Drug resistance trends among previously treated tuberculosis patients in a national registry in Peru, 1994-2001

International Journal of Tuberculosis and Lung Disease

Volumn 8, Issue 4, 2004, Pages 465-472

  Vasquez Campos L ^a   Asencios Solis, L ^a   Leo Hurtado, E ^a   Quispe Torres, N ^a   Salazar Lindo, E ^a,b   Bayona, J ^c,d   Becerra, Mercedes C ^d  

^a INSTITUTO NACIONAL DE SALUD   (Peru)

^b UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^c Soc Salud Sucursal Peru/Part Hlth   (Peru)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

MDR TB; National reference laboratory; Surveillance; Treatment failure

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; DRUG RESPONSE; HEALTH SURVEY; HUMAN; LABORATORY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PERU; PRIORITY JOURNAL; REGISTER; RETREATMENT; RETROSPECTIVE STUDY; TREATMENT FAILURE; TREATMENT PLANNING; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ETHAMBUTOL; HUMANS; ISONIAZID; PERU; PYRAZINAMIDE; REGISTRIES; RETROSPECTIVE STUDIES; RIFAMPIN; STREPTOMYCIN; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 2442464989     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Snider D E Jr, Castro K G. The global threat of drug-resistant tuberculosis. N Engl J Med 1998; 338: 1689-1690.
2. Espinal M A. Report: multidrug resistant tuberculosis (MDR TB): basis for the development of an evidence-based case-management strategy for MDR-TB within the WHO's DOTS strategy. Proceedings of 1998 Meetings and Protocol Recommendations. WHO/TB/99.260. Geneva, Switzerland: World Health Organization; 1999.
3. World Health Organization. Coordination of DOTS-Plus pilot projects for the management of MDR-TB. WHO/CDS/CBC/TB/99.262. Geneva, Switzerland: WHO, 1999.
4. Gupta R, Cegielski J P, Espinal M A, et al. Increasing transparency in partnerships for health-introducing the Green Light Committee. Trop Med Int Health 2002; 7: 970-976.
5. Farmer P E, Kim J Y. Community-based approaches to the control of multidrug-resistant tuberculosis: introducing "DOTS-plus". Brit Med J 1998; 317: 671-674.
6. Iseman M D. MDR-TB and the developing world-a problem no longer to be ignored: the WHO announces 'DOTS Plus' strategy. Int J Tuberc Lung Dis 1998; 2: 867.
7. World Health Organization. Progress in DOTS-Plus and the management of multidrug-resistant tuberculosis (MDR-TB). WHO/CDS/TB/2001.292. Geneva, Switzerland: WHO, 2001.
8. Programa Nacional de Control de Tuberculosis. Tuberculosis En El Peru: Informe 1995. Lima, Peru: Ministerio de Salud, 1996.
9. Programa Nacional de Control de Tuberculosis. Tuberculosis En El Peru: Informe 1996. Lima, Peru: Ministerio de Salud, 1997.
10. World Health Organization. Global tuberculosis control. WHO Report 2001. WHO/CDS/TB/2001.287. Geneva, Switzerland: WHO, 2001.
11. Programa Nacional de Control de Tuberculosis. Tuberculosis en el Perú. Informe 1999 Lima, Peru: Ministerio de Salud, 2000.
12. Suarez P G, Floyd K, Portocarrero J, et al. Feasibility and cost-effectiveness of standardized second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 2002; 359: 1980-1989.
13. Chavez-Pachas A M. Time to smear- and culture-conversion in patients receiving a standardized regimen for MDR-TB, in the Direccion de Salud V, Lima, Peru, 1997-2000. Int J Tuberc Lung Dis 2001; 5 (Suppl. 1): S255.
14. Espinal M A, Kim S J, Suarez P G, et al. Standard short-course chemotherapy for drug resistant tuberculosis: treatment outcomes in six countries. JAMA 2000; 283: 2537-2545.
15. Jave O, Castilla T, Prado A, Asto T. Drug-susceptibility testing to antituberculous drugs in new patients who fail Category 1 regimen 2RHZE/4R2H2. (Poster) Guayaquil, Ecuador: IUATLD Latin American Region Conference, 24-27 October 2000.
16. Chávez Pachas A M, Blank R, Smith Fawzi M C, Bayona J, Becerra M C, Mitnick C D. Identifying early treatment failure on Category I therapy for pulmonary tuberculosis in Lima Ciudad, Peru. Int J Tuberc Lung Dis 2004; 8: 52-58.
17. Iseman M D. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993; 329: 784-791.
18. Centers for Disease Control. Initial therapy for tuberculosis in the era of multidrug resistance: recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR 1993; 42: 1-8.
19. Frieden T R, Fujiwara E, Washko R, Hamburg M. Tuberculosis in New York City-turning the tide. N Engl J Med 1995; 333: 229-233.
20. World Health Organization/International Union Against Tuberculosis and Lung Disease Global Project on Anti-tuberculosis Drug Resistance Surveillance. Anti-tuberculosis drug resistance in the world, 1994-1997. WHO/TB/97.229. Geneva, Switzerland: WHO, 1997.
21. World Health Organization/International Union Against Tuberculosis and Lung Disease Global Project on Anti-tuberculosis Drug Resistance Surveillance. Anti-tuberculosis drug resistance in the world, 2000. WHO/CDS/TB/2000.278. Geneva, Switzerland: WHO, 2000.
22. Hopewell P C, Ganter B, Baron R B, Sanchez-Hernandez M. Operational evaluation of treatment for tuberculosis. Results of 8- and 12-month regimens in Peru. Am Rev Respir Dis 1985; 132: 737-741.
23. Vasquez L, Asencios L, Quispe N, et al. Vigilancia de la resistencia a los medicamentos antituberculosos en el Perú, 1995-1996. Rev Med Exp INS-PERU 1997; 14: 5-14.
24. Programa Nacional de Control de Tuberculosis. Tuberculosis en el Peru: Informe 2000. Lima, Peru: Ministerio de Salud, 2001.
25. Canetti G, Rist N, Grosset J. Mésure de la sensibilité du bacille tuberculeux aux drogues antibacillaires pour la méthode des proportions. Rev Tuberc (Paris) 1963; 27: 217-272.
26. Centro Panamericano de Zoonosis. Manual de normas y procedimientos técnicos para la bacteriología de la tuberculosis. Buenos Aires, Argentina: CEPANZO/OPS/OMS, 1988.
27. Wayne L G. Simple pyrazinamide and urease test for routine identification of mycobacteria. Am Rev Respir Dis 1974; 109: 147-151.
28. Bureau of Tuberculosis Control. Clinical policies and protocols. 3rd ed. New York, NY: New York City Department of Health, 1999.
29. Altman D G. Practical statistics for medical research. London, UK: Chapman and Hall, 1991.
30. Heifets L B, Cangelosi G A. Drug susceptibility testing of M. tuberculosis: a neglected problem at the turn of the century. Int J Tuberc Lung Dis 1999; 3: 564-581.
31. Grosset J. Systematic drug susceptibility testing: a necessary component of the 'DOTS Plus' strategy? Int J Tuberc Lung Dis 1999; 3: 549-550.
32. Nunn P, Felten M. Surveillance of resistance to antituberculosis drugs in developing countries. Tubercle Lung Dis 1994; 75: 163-167.
33. Chaulet P, Boulahbal F, Grosset J. Surveillance of drug resistance for tuberculosis control: why and how? Tubercle Lung Dis 1995; 76: 487-492.
34. Van Deun A, Salim A H, Rigouts L, Rahman M, Fissette K, Portaels E Evaluation of tuberculosis control by periodic or routine susceptibility testing in previously treated cases. Int J Tuberc Lung Dis 2001; 5: 329-338.
35. Suarez P G, Watt C J, Alarcon E, et al. The dynamics of tuberculosis in response to 10 years of intensive control effort in Peru. J Infect Dis 2001; 184: 473-478.
36. World Health Organization, International Union Against Tuberculosis and Lung Disease. Guidelines for surveillance of drug resistance in tuberculosis. Int J Tuberc Lung Dis 1998; 2: 72-89.
37. Manalo F, Tan F, Sbarbaro J A, Iseman M D. Community-based short-course treatment of pulmonary tuberculosis in a developing nation. Initial report of an eight-month, largely intermittent regimen in a population with a high prevalence of drug resistance. Am Rev Respir Dis 1990; 142(6 Pt. 1): 1301-1305.
38. Mitchison D A, Nunn A J. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986; 133: 423-430.
39. Farmer P E, Bayona J, Becerra M, et al. The dilemma of MDR-TB in the global era. Int J Tuberc Lung Dis 1998; 2: 869-876.
40. Van Deun A, Aung K J, Chowdhury S, et al. Drug susceptibility of M. tuberculosis in a rural area of Bangladesh and its relevance to the national treatment regimens. Int J Tuberc Lung Dis 1999; 3: 143-148.
41. Rieder H. Recommendations for the control and treatment of tuberculosis. Paris, France: International Union Against Tuberculosis and Lung Disease, 2002.
42. Bastian I, Rigouts L, Van Deun A, Portaels F. Directly observed treatment, short-course strategy and multidrug-resistant tuberculosis: are any modifications required? Bull World Health Organ 2000; 78: 238-251.
43. Jave H O, Castilla T, Perez A. Treatment of TB relapse with DOTS regimen. Int J Tuberc Lung Dis 2001; 5 (Suppl 1): S204.
44. Kam K M, Yip C W. Surveillance of M. tuberculosis drug resistance in Hong Kong, 1986-1999, after the implementation of directly observed treatment. Int J Tuberc Lung Dis 2001; 5: 815-823.
45. Zhang L X, Tu D H, Enarson D A. The impact of directly-observed treatment on the epidemiology of tuberculosis in Beijing. Int J Tuberc Lung Dis 2000; 4: 904-910.
46. Jasmer R M, Hahn J A, Small P M, et al. A molecular epidemiologic analysis of tuberculosis trends in San Francisco, 1991-1997. Ann Intern Med 1999; 130: 971-978.
47. Fujiwara P I, Cook S V, Rutherford C M, et al. A continuing survey of drug-resistant tuberculosis, New York City, April 1994. Arch Intern Med 1997; 157: 531-536.
48. Liu Z, Shilkret K L, Finelli L. Epidemiology of drug-resistant tuberculosis in New Jersey from 1991 to 1995. Int J Epidemiol 1998; 27: 121-126.
49. Shafer R W, Small P M, Larkin C, et al. Temporal trends and transmission patterns during the emergence of multidrug-resistant tuberculosis in New York City: a molecular epidemiological assessment. J Infect Dis 1995; 171: 170-176.
50. Moore M, Onorato I M, McCray E, Castro K G. Trends in drug-resistant tuberculosis in the United States, 1993-1996. JAMA 1997; 278: 833-837.